AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06564051 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT01673919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 104 weeks
Study NCT02790736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: active treatment
Study NCT02790736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive pill
Study NCT04854473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exero Medical Leak Detection System
Description: the Exero Leak Detection System components used in this study are:~* Smart drain - a surgical drain with added sensing electrodes~* Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~* Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes.
Study NCT04023058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mitral surgery
Description: Guidelines approved mitral surgery
Study NCT01241773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Two 75 mg capsules once daily for 14 days
Study NCT01241773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: One 600 mg tablet once daily for 14 days
Study NCT04023058 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mitral surgery
Description: Guidelines approved mitral surgery
Study NCT01893086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LH alone
Description: LH, laparoscopic hysterectomy
Study NCT01893086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LH with opportunistic salpingectomy
Description: LH, laparoscopic hysterectomy
Study NCT03287986 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Structural and functional sequences
Study NCT00370084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride
Description: oral, three times daily
Study NCT04753476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of Secretome-MSCs
Description: Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours
Study NCT04753476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard treatment of Covid-19
Description: Patients will be given Standard treatment of Covid-19 which accordance with National protocol
Study NCT04753476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment of Covid-19
Description: Patients will be given Standard treatment of Covid-19 which accordance with National protocol
Study NCT00551044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Bicalutamide 150mg once daily, oral administration, for 12 months
Study NCT00978471 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thiotepa
Description: Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
Study NCT00978471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
Study NCT00490555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dutasteride
Description: placebo pill for 12 weeks
Study NCT00490555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo dutasteride
Description: placebo pill for 12 weeks
Study NCT00490555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DMPA
Description: placebo DMPA injection Once
Study NCT03782038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCD
Description: Micro coring skin removal with automated coring device
Study NCT01385371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass (Phleum pratense) pollen allergen extract
Description: One dissolving tablet sublingually once daily
Study NCT01385371 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SCH 697243
Description: One dissolving tablet sublingually once daily
Study NCT00915356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Study NCT00915356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Study NCT04253912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP-245
Description: 2% Povidone-Iodine Gel
Study NCT04253912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel (no Povidone-Iodine)
Description: Placebo Gel (no Povidone-Iodine)
Study NCT00568503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX028
Study NCT00568503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00568503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide
Study NCT03537885 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Electrodes are placed on that head to deliver a non-invasive brain stimulation to the target area.
Study NCT03537885 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: A coil is held tangential to the head in order to deliver a non-invasive brain stimulation to the target area.
Study NCT03537885 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: A cap is placed on the head with sensors to detect brain activity during the intervention.
Study NCT01580943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
Study NCT01580943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?).
Study NCT01649427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
Study NCT02623478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study NCT02623478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study NCT02644031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mtwo rotary system
Description: post-treatment pain after using mtwo rotary system
Study NCT02644031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: safe-sider rotary system
Description: post-treatment pain after using safe-sider rotary system
Study NCT02644031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand files
Description: post-treatment pain after using hand files
Study NCT01841307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Study NCT00370084 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, three times daily
Study NCT00213525 — intervention group
Intervention type: OTHER
Intervention: Questionnary for environmental factors research
Description: Questionnary for environmental factors research
Study NCT04645420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global gene expression profiles obtained from synovial biopsies.
Description: Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
Study NCT04627337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii 250 MG
Description: Probiotic yeast in capsules
Study NCT04627337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice following a low fermentation diet
Description: Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
Study NCT04627337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice following a low fermentation diet
Description: Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
Study NCT00546650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan succinate
Description: NP101 iontophoretic transdermal system
Study NCT00546650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan succinate
Description: oral, subcutaneous, and intranasal formulations
Study NCT04102956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kallikrein
Description: HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
Study NCT00386607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg
Study NCT00386607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 320 mg
Study NCT00386607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: Hydrochlorothiazide (HCTZ) 12.5-25 mg
Study NCT00853034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FOS-IN
Description: prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening
Study NCT00853034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AXOS
Description: arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening
Study NCT04105283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tc99m-MAA
Description: Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
Study NCT00673946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: True saturation values displayed
Description: Physicians will be presented with real saturations.
Study NCT00673946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered saturation values displayed.
Description: Physicians will be presented with saturation measurements three percentage points above the true values.
Study NCT02522962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GroupCoreSIT
Description: Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training.
Study NCT02522962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
Study NCT02290327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Proton pump inhibitor
Study NCT04266860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental - Test Results and Education
Description: First, these providers will receive educational materials (e.g. a slide deck, mock test result and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the DxTerity test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the DxTerity test at the clinically-appropriate point in each case.
Study NCT03278080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement
Study NCT03737916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 cc 5% Dextrose solution
Description: Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
Study NCT03737916 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5 cc salin
Description: Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
Study NCT03790241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of a catheter
Description: Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
Study NCT00264381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin sodium injection
Description: Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
Study NCT01830309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 200mg
Description: Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition
Study NCT02909517 — intervention group
Intervention type: OTHER
Intervention: cSLO imaging
Study NCT03462602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NGT group
Description: After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was retained until the return of bowel function (passage of flatus or passage of stool) in the patients assigned to the NGT group.
Study NCT03462602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-NGT group
Description: After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was removed in the operation room immediately after the surgery in those assigned to the non-NGT group.
Study NCT00564343 — intervention group
Intervention type: OTHER
Intervention: water based training program to improve balance
Description: The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
Study NCT00623558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
Study NCT00623558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
Study NCT00623558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
Study NCT00623558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
Study NCT00623558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
Study NCT02814708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTSST-1v
Description: Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow-up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST-1 binding Ab titer of \< 20 to > 40 or a 4-fold increase in TSST-1 binding Ab titer .
Study NCT02814708 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rTSST-1v
Description: Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow-up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST-1 binding Ab titer of \< 20 to > 40 or a 4-fold increase in TSST-1 binding Ab titer .
Study NCT03442192 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PrEP Care Anywhere Services
Description: PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~* On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~* HIV and Sexually Transmitted Infection (STI) at Home Self-Testing
Study NCT03129061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Description: * Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~* Anti PD-1 per standard of care~* Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~* \[18F\]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose.
Study NCT03129061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Description: * Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to treatment.~* Anti PD-1, single dose~* Blood sampling, tumor biopsy and \[18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection.
Study NCT03990116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral
Description: Posture lateral kangaroo care
Study NCT03990116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone
Description: Posture prone kangaroo care
Study NCT01953172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AMP-886
Description: AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
Study NCT03578263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby.